Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Xbrane Biopharma AB is a Sweden-based biotechnology company specializing in the development, manufacture, and commercialization of biosimilars. These follow-on biologics target high-cost originator drugs, aiming to provide affordable alternatives for treating serious conditions such as eye diseases, rheumatoid arthritis, psoriasis, cancer, and prostate cancer. The company leverages a patented protein production platform using E. coli host cells, delivering up to 12 times higher productivity and up to 80% cost reductions compared to standard systems, enabling competitive biosimilar development. Key products include Ximluci (also known as Xlucane), a ranibizumab biosimilar for wet age-related macular degeneration, diabetic macular edema, and other retinal disorders; XB003 and BIIB801, certolizumab pegol biosimilars for autoimmune diseases like rheumatoid arthritis and psoriasis; Xdivane, a PD-1 inhibitor nivolumab biosimilar for various cancers; Xdarzane, a daratumumab biosimilar; and Spherotide (formerly Sperotide), a generic slow-release injectable for prostate cancer. Founded in 2008 at Stockholm University and headquartered in Solna, Xbrane Biopharma AB employs 26 people and generates revenue primarily from biosimilar development, with sales reaching 199 million SEK in 2024 across North America, Germany, and India. It plays a vital role in expanding access to biological therapies in the global biotechnology sector.
kr 0.89
kr 0.02 (-1.98%)
Live · 10:08 PM · Twelve Data
The business is unprofitable at the operating level (-44.72% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue growth slowed to 2.9%, essentially flat. This is a business that needs a catalyst.
Negative free cash flow of -kr 390M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 77M
▲ +2.9% YoY
Net Income (TTM)
kr 106M
▲ +147.8% YoY
Op. Margin
-138.99%
▲ +35.8pp YoY
ROIC
-10.57%
▲ +12.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 317M
▼ -109.9% YoY
Op. Cash Flow (TTM)
kr 176M
▲ +244.5% YoY
Net Debt
-kr 28M
Net Cash Position
Cash & Equiv.
kr 87M
3Y CAGR: +38.2%
Continue Research
Xbrane Biopharma AB (publ) (XBRANE.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Xbrane Biopharma AB (publ) scores 46/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Xbrane Biopharma AB (publ) scores 46 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -139.0% operating margin and a -10.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh XBRANE.XSTO's valuation and scores 46/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.